Labcorp Announces Retirement of Dr. R. Sanders Williams and Mr. Jean-Luc Bélingard From Its Board of Directors

BURLINGTON, N.C., -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced that Dr. R. Sanders Williams and Mr. Jean-Luc Bélingard have retired from its board of directors at the conclusion of their current terms on May 14, 2024.

Dr. Williams and Mr. Bélingard retired from the board pursuant to the company's corporate governance guidelines, which provide for a mandatory director retirement at the conclusion of the term during which they reach the age of 75, subject to limited exceptions.

"We are grateful for the many years of invaluable expertise that Sandy and Jean-Luc have provided to Labcorp in support of our mission to improve health and improve lives," said Adam Schechter, chairman and CEO. "They helped shape our growth strategy and make advancements in science, technology and innovation all grounded in a firm commitment to business accountability, transparency and compliance."

Dr. Williams became a director of Labcorp in 2007 and has served as the Quality and Compliance Committee Chair and on the Audit Committee. He is a Professor of Medicine and Senior Advisor for Science and Technology at Duke University and President Emeritus of the J. David Gladstone Institutes.

Mr. Bélingard became a director of Labcorp in 1995 and has served on the Compensation and Human Capital and Quality and Compliance committees. He is an Operating Advisor to Clayton, Dubilier & Rice, Vice President of Institut Mérieux and Former Chairman and CEO of bioMérieux-Pierre Fabre.

"Sandy and Jean-Luc have made a tremendous impact on Labcorp, providing strong leadership and keen insights that fueled our growth," said Dr. Garheng Kong, lead independent director and chair of the Nominating and Corporate Governance Committee. "We thank them for their commitment to making Labcorp a trusted, global leader of innovative laboratory services while delivering value for customers, shareholders and employees."

About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's more than 67,000 employees serve clients in approximately 100 countries, provided support for 84% of the new drugs and therapeutic products approved in 2023 by the FDA, and performed more than 600 million tests for patients around the world. Learn more about us at www.labcorp.com.

SOURCE Labcorp

Media: Kimbrel Arculeo, 336-436-8263, [email protected]; Investors: Christin O'Donnell, 336-436-5076, [email protected]

NewsroomIn the News